RaQualia Pharma Inc. Logo

RaQualia Pharma Inc.

An R&D firm discovering novel small molecules for out-licensing to pharma partners.

4579 | T

Overview

Corporate Details

ISIN(s):
JP3967150008
LEI:
Country:
Japan
Address:
名古屋市中村区名駅南一丁目21番19号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RaQualia Pharma Inc. is a research and development-focused drug discovery company that originated as a spin-off from Pfizer's research laboratories. The company specializes in the discovery and early-stage development of novel pharmaceutical compounds, or 'seeds' for new drugs, with a focus on small molecules. Its primary business model involves creating these development compounds and then generating revenue through out-licensing agreements and partnerships with other pharmaceutical companies for late-stage development and commercialization. RaQualia actively leverages an open collaboration network with academic and industry partners to advance its pipeline. The company is also expanding into new therapeutic modalities, such as targeted protein degradation, to address previously 'undruggable' targets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:58
Report Publication Announcement
確認書
Japanese 8.2 KB
2025-08-14 08:57
Interim Report
半期報告書-第18期(2025/01/01-2025/12/31)
Japanese 229.8 KB
2025-04-18 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.1 KB
2025-03-31 09:01
Registration Form
訂正有価証券届出書(参照方式)
Japanese 155.4 KB
2025-03-31 08:31
Registration Form
訂正確認書
Japanese 8.2 KB
2025-03-31 08:30
Annual Report
訂正有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 811.9 KB
2025-03-26 08:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 158.4 KB
2025-03-26 07:52
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2025-03-26 07:51
Registration Form
確認書
Japanese 8.2 KB
2025-03-26 07:50
Governance Information
内部統制報告書-第17期(2024/01/01-2024/12/31)
Japanese 23.1 KB
2025-03-26 07:49
Annual Report
有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 1.4 MB
2025-03-21 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 282.6 KB
2024-12-13 08:00
Board/Management Information
臨時報告書
Japanese 20.7 KB
2024-10-01 09:04
Share Issue/Capital Change
訂正臨時報告書
Japanese 35.8 KB
2024-09-13 08:31
Share Issue/Capital Change
臨時報告書
Japanese 37.9 KB

Automate Your Workflow. Get a real-time feed of all RaQualia Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RaQualia Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RaQualia Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

QUINSTREET, INC Logo
AI-driven marketplaces connecting consumers to brands in finance & home services on a pay-per-result basis.
United States of America
QNST
Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America
REFR

Talk to a Data Expert

Have a question? We'll get back to you promptly.